Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Breast Neoplasms 1

Interventions

Prednisone 103enzalutamide 76Docetaxel 72Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24radium Ra 223 dichloride 22pembrolizumab 22darolutamide 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Verteporfin × Clear all
NCT03067051 2026-05-01

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

SpectraCure AB

Phase 1/2 Recruiting
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT06807359 2026-05-01

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

SpectraCure AB

Phase 1/2 Recruiting
43 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡